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TO THE EDITOR
Imatinib mesylate (STI571, Glivec) is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, created by the Philadelphia translocation, t(9;22)(q34;q11) (Ph+) of chronic myeloid leukemia (CML). In the first studies, the drug appears to be very effective and generally well tolerated, [1] [2] [3] but as it is only recently introduced, few data are available about long-term effects, specifically the possibility of secondary malignancies. Recently, several patients have been noticed to develop clonal karyotype abnormalities in Philadelphia translocation negative cells (Ph−). [4] [5] [6] [7] Since November 2000 we studied 274 patients treated with Imatinib in chronic-phase CML resistant and/or intolerant to interferon ␣, accelerated phase and blast crisis. Cytogenetic data at onset of treatment and at least one follow-up are available for 200 cases. Four patients who achieved complete or major response show persistent clonal abnormalities in their Ph− cells.
We compared this with our historical population of patients with CML, studied between 1 January 1990 and 9 November 2001, treated according to different protocols. 434 patients were studied, 227 remained 100% Ph+. 207 had (partial) cytogenetic remissions. Of this last group, three had non-clonal abnormalities and two had clonal, but transient abnormalities in the Ph− clone. [5] ). FISH confirmed the presence of monosomy 7 in 28 to 56% of cells and trisomy 8 in 5 to 9%, at various time-points (Table 1) .
Clinically she is in hematologic remission and there is no evidence of myelodysplastic syndrome (MDS), only of macrocytosis, which is not unusual during any cytotoxic therapy.
Case 2: A man was diagnosed with CML in 1994 at the age of 37. He became refractory to interferon ␣, and had an autologous transplant in accelerated phase, 4 years ago. He was maintained in hematologic response with interferon ␣, with 100% Ph+ mitoses (46,XY,t(9;22)(q34;q11) [30] ). In December 2000 treatment with imatinib (400 mg daily) was started for CML in acceleration. After 3 months he presented with pancytopenia and myelodysplastic features in the bone marrow. The karyotype was 46,XY,t(9;22)(q34;q11) [4] /45,XY,−7 [3] . After 6 and 9 months therapy all cells showed trisomy 8 (47,XY,+8 [20] ). An isolated t(4;8)(q22;p22) appeared in one mitosis on three separate occasions, in two on his last check up. The last three occurrences were after starting imatinib. Clinically he is in remission, without signs of MDS.
We present four patients with sustained clonal abnormalities in Ph− cells during imatinib therapy.
Two patients developed two abnormal clones characterized by trisomy 8 and monosomy 7: in case 1 monosomy 7 was prevalent and in case 2 it was the trisomy 8 (Table 1) . Trisomy 8 is a non random abnormality most frequent in myeloproliferative disorders, including CML, while monosomy 7 is more related to secondary MDS and AML.
In two other cases, the abnormal clone is characterized by unusual translocations which were found already in one cell (therefore not clonal) after interferon ␣ treatment. After imatinib, these Ph− aberrant clones persisted and seemed to gain in importance. The emergence of clonal aberrations in the Ph− cell population, after interferon ␣ therapy has also been reported (reviewed in Ref. 6 ). The persistence (and increase) of the abnormality after imatinib confirms the clonality of the cytogenetic change.
Very recently, Andersen et al 6 reported similar observations, reviewed the literature and discussed the possible mechanisms. We agree with these authors that the proliferative advantage of the Ph+ cells may have masked a pre-existing aberration. On the other hand, these patients were heavily pretreated which may have induced these cytogenetic changes. 5 In addition, it cannot be excluded that imatinib has a role in mutagenesis or immune suppression. All these possibilities need further examination. Whether these new Ph− aberrant clones, not sensitive to imatinib will herald a new pathology (MDS, AML) await further follow-up. In our series, up until now, only case 2 shows actual MDS (with some reservations because of the ongoing treatment with imatinib), but close follow-up is needed.
The frequency of this phenomenon is relatively high after imatinib and is probably due to the efficacy of the drug in suppressing the Ph+ clone 
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